These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30573777)

  • 1. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
    Schetelig J; de Wreede LC; van Gelder M; Koster L; Finke J; Niederwieser D; Beelen D; Mufti GJ; Platzbecker U; Ganser A; Heidenreich S; Maertens J; Socié G; Brecht A; Stelljes M; Kobbe G; Volin L; Nagler A; Vitek A; Luft T; Ljungman P; Yakoub-Agha I; Robin M; Kröger N
    Leukemia; 2019 Mar; 33(3):686-695. PubMed ID: 30573777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
    Duncan CN; Majhail NS; Brazauskas R; Wang Z; Cahn JY; Frangoul HA; Hayashi RJ; Hsu JW; Kamble RT; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Maziarz RT; Mehta P; Myers KC; Norkin M; Pidala JA; Porter DL; Reddy V; Saber W; Savani BN; Schouten HC; Steinberg A; Wall DA; Warwick AB; Wood WA; Yu LC; Jacobsohn DA; Sorror ML
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):151-8. PubMed ID: 25316109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
    Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
    Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
    Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
    J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
    Kröger N; Brand R; van Biezen A; Zander A; Dierlamm J; Niederwieser D; Devergie A; Ruutu T; Cornish J; Ljungman P; Gratwohl A; Cordonnier C; Beelen D; Deconinck E; Symeonidis A; de Witte T;
    Haematologica; 2009 Apr; 94(4):542-9. PubMed ID: 19278968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.
    Bejanyan N; Weisdorf DJ; Logan BR; Wang HL; Devine SM; de Lima M; Bunjes DW; Zhang MJ
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):454-9. PubMed ID: 25460355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
    Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
    Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
    Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD
    Pandya BJ; Burns LJ; Wang T; Xie B; Touya M; Spalding J; Block A; Kuperman G; Young C
    Transplant Cell Ther; 2024 Jul; 30(7):683.e1-683.e13. PubMed ID: 38663769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Vydra J; Válková V; Čemusová B; Kolář M; Nováková L; Soukup P; Šálek C; Vraná M; Pytlík R; Lesný P; Vítek A; Cetkovský P; Marková M
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):365-371. PubMed ID: 30905537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
    Koh H; Nakamae H; Hagihara K; Nakane T; Manabe M; Hayashi Y; Nishimoto M; Umemoto Y; Nakamae M; Hirose A; Inoue E; Inoue A; Yoshida M; Bingo M; Okamura H; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Ohsawa M; Hino M
    J Exp Clin Cancer Res; 2011 Apr; 30(1):36. PubMed ID: 21477348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.